This is a multicenter prospective observational study aimed to asses whether a specific prothrombotic platelet phenotype can discern migraine patients with PFO (patent forame ovale) - related symptoms from patients with incidental PFO. The study will also explore additional distinguishing features of causal and incidental PFO using a metabolomics approach. It involves the enrollment of well-characterized patient cohorts and an ex vivo approach using comparative cell biology models that reproduce the most critical aspects of the clinical scenario.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of migraineurs patients with Platelet activation
Timeframe: through study completion, an average of 2 years
Number of migraineurs patients with high Thrombin generation levels
Timeframe: through study completion, an average of 2 years
levels of the oxidative status in PFO patients
Timeframe: through study completion, an average of 2 years
Number of migraineurs patients with Untargeted metabolomics
Timeframe: through study completion, an average of 2 years